Among patients with varying subtypes of sarcoma who were undergoing treatment with dasatinib, the drug failed to achieve control of sarcoma growth for at least 6 months in more than half, according to a study published in Cancer.1
In a phase 2 study of dasatinib, researchers led by Scott Schuetze, MD, PhD, of the University of Michigan in Ann Arbor enrolled 116 patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor through a single indolent sarcoma cohort.
With a primary objective of estimating 6-month progression-free survival rate according to the Choi criteria with a target of at least 50%, the researchers performed cross-sectional imaging before the start of treatment, every 2 months for 6 months, as well as every 3 months throughout treatment.
Among 109 patients who began treatment with dasatinib, 6-month progression-free survival was 48%. Median progression-free survival was 5.8 months.
Among all 5 observed subtypes, the 2-year overall survival rate was 44% and the 5-year overall survival rate was 13%. The researchers observed an 18% objective response rate among patients with chondrosarcoma or chordoma.
Progression-free survival rate was highest with alveolar soft part sarcoma and lowest with solitary fibrous tumor at 6 months. More than 10% of patients with alveolar soft part sarcoma, chondrosarcoma, or chordoma had stable disease for more than 1 year.
- Schuetze SM, Bolejack V, Choy E, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2016 Sep. doi: 10.1002/cncr.30379 [Epub ahead of print]